Biosergen AB (BIOSGN.ST)
SEK 0.3
(1.35%)
SEK 0.3
(1.35%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 7.2 Million SEK | -78.69% |
| 2022 | 33.79 Million SEK | 14.6% |
| 2021 | 29.48 Million SEK | 514.68% |
| 2020 | 4.79 Million SEK | -28.17% |
| 2019 | 6.67 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 19.18 Million SEK | -24.73% |
| 2024 Q1 | 25.48 Million SEK | 253.94% |
| 2023 Q4 | 7.2 Million SEK | -37.29% |
| 2023 FY | 7.2 Million SEK | -78.69% |
| 2023 Q3 | 11.48 Million SEK | -33.85% |
| 2023 Q2 | 17.36 Million SEK | -31.61% |
| 2023 Q1 | 25.38 Million SEK | -24.87% |
| 2022 Q2 | 13.61 Million SEK | -26.23% |
| 2022 Q1 | 18.45 Million SEK | -37.4% |
| 2022 FY | 33.79 Million SEK | 14.6% |
| 2022 Q4 | 33.79 Million SEK | 161.25% |
| 2022 Q3 | 12.93 Million SEK | -5.02% |
| 2021 Q2 | 43.21 Million SEK | 15613.82% |
| 2021 Q4 | 29.48 Million SEK | -26.73% |
| 2021 Q3 | 40.24 Million SEK | -6.87% |
| 2021 FY | 29.48 Million SEK | 514.68% |
| 2021 Q1 | 275 Thousand SEK | 0.0% |
| 2020 FY | 4.79 Million SEK | -28.17% |
| 2019 FY | 6.67 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alzinova AB (publ) | 123.18 Million SEK | 94.155% |
| Amniotics AB (publ) | 26.08 Million SEK | 72.395% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -18.496% |
| BioArctic AB (publ) | 1.18 Billion SEK | 99.393% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 99.621% |
| Genovis AB (publ.) | 288.85 Million SEK | 97.507% |
| LIDDS AB (publ) | 17.65 Million SEK | 59.213% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 97.417% |
| OncoZenge AB (publ) | 20.34 Million SEK | 64.597% |
| Saniona AB (publ) | 64.14 Million SEK | 88.774% |
| Simris Alg AB (publ) | 174.55 Million SEK | 95.875% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 98.549% |
| AcouSort AB (publ) | 34.51 Million SEK | 79.135% |
| Active Biotech AB (publ) | 44 Million SEK | 83.634% |
| Camurus AB (publ) | 1.9 Billion SEK | 99.623% |
| Cantargia AB (publ) | 223.71 Million SEK | 96.781% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | 51.57% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 91.551% |
| Mendus AB (publ) | 755.95 Million SEK | 99.047% |
| Kancera AB (publ) | 65.64 Million SEK | 89.03% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 99.428% |
| Lipum AB (publ) | 12.11 Million SEK | 40.537% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | 78.57% |
| NextCell Pharma AB | 81.28 Million SEK | 91.141% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 98.898% |
| Xintela AB (publ) | 18.39 Million SEK | 60.853% |
| Ziccum AB (publ) | 14.97 Million SEK | 51.904% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | 76.134% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | 64.069% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 94.878% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 99.059% |
| CombiGene AB (publ) | 120.61 Million SEK | 94.03% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 96.682% |
| Intervacc AB (publ) | 259.61 Million SEK | 97.226% |
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 93.921% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 88.456% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | 82.838% |
| Corline Biomedical AB | 100.1 Million SEK | 92.807% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 95.934% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 88.414% |
| Aptahem AB (publ) | 63.02 Million SEK | 88.574% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 97.95% |
| Fluicell AB (publ) | 9.34 Million SEK | 22.901% |
| Biovica International AB (publ) | 131.4 Million SEK | 94.52% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 86.409% |
| Abliva AB (publ) | 87.49 Million SEK | 91.77% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 99.053% |
| 2cureX AB (publ) | 16.62 Million SEK | 56.686% |
| I-Tech AB | 152.44 Million SEK | 95.276% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 99.293% |
| Cyxone AB (publ) | 43.65 Million SEK | 83.505% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 90.849% |
| Nanologica AB (publ) | 77.42 Million SEK | 90.7% |
| SynAct Pharma AB | 228.01 Million SEK | 96.842% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | 73.093% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 99.486% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | 66.82% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 96.979% |
| Pila Pharma AB (publ) | 8.45 Million SEK | 14.831% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 91.73% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | 74.74% |